Het gebruik van langwerkende lanreotide als behandeling voor volume-afname van polycysteuze lever

- mininum leeftijd 18 jaar
- multiple cystes >19
- Cooperating patiënt
- Wil meedoen aan de studie en volgt het behandelplan

· Use of oral anticonceptives or estrogen suppletion
· Females who are pregnant or breast-feeding
· History or other evidence of chronic pulmonary disease associated with functional limitation
· History of severe cardiac disease (eg, NYHA Functional Class III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases). In addition, patients with documented or presumed coronary artery disease or cerebrovascular disease should not be enrolled.
· History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
· Symptomatic gallstones (lanreotide decreases gall bladder volume)
· Renal failure requiring hemodialysis